Navigation Links
Regional Biotech Association Warns Vermont Legislation Could Have Profound Negative Impact

- Shumlin Promoting Senate Bill S. 48 Today; Will Thwart Burgeoning Biotechnology Industry, Costing Jobs and Research Funds in Vermont -

MONTPELIER, Vt., March 27 /PRNewswire/ -- The region's largest biotechnology association today warned that a bill under consideration by the Vermont Legislature will create the most restrictive and onerous regulatory environments for biotechnology growth and development not only in New England, but in the entire nation. Senate Bill 48, an Act Relating to the Marketing of Prescribed Products, is the focus of a presentation today at the State House by Senate President Peter Shumlin.

"The Legislation's radical expansion of Vermont's existing and strict biopharmaceutical marketing laws promises to hinder significantly the development of the biotechnology industry in this state," said Paula Newton, Chair of the New England Biotech Association (NEBA).

NEBA serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical community, representing state biotech associations, companies, academic institutions, and other organizations consisting of more than 800 entities.

Vermont law already heavily regulates biopharmaceutical marketing activities by requiring the disclosure of the value, nature and purpose of certain marketing related expenses by pharmaceutical manufacturers of just $25 or more in value, among other things. The bill would expand existing regulation by limiting compensation and other payments between biopharmaceutical manufacturers and physicians -- including educational materials. And it would broadly expand already onerous disclosure requirements to include competitively sensitive information concerning clinical trials. Furthermore, IMS Health this month reported that annual U.S. prescription sales growth was just 1.3 percent in 2008, the lowest rate since 1963, according to data maintained by CMS -- making the stated purpose of the Legislation, controlling drug costs, moot.

"With the enactment of these over-the-top restrictions, Vermont's pharmaceutical marketing law will be far more severe than those of any other New England state. Such a uniquely sweeping expansion of the regulatory climate in Vermont will have a chilling effect on the growth of the industry in this state," said Newton. "These requirements would certainly discourage biotechnology manufacturers from participating in clinical trials and academic research in Vermont, since reported information would include competitively sensitive and proprietary information, making it more prudent to conduct research in one of the 49 other states," she continued. "We urge reasonable elected officials who care about future jobs and the health care system in Vermont to reject this legislation."

Two other states, Colorado and New Mexico, have recently rejected marketing restriction legislation far less extreme than the Vermont bill as bad policy with unintended negative consequences for the life sciences industry and the jobs it produces

NEBA is a non-profit, member-driven organization comprised of state biotech associations, companies, academic institutions, and other organizations with a collective mission to support and grow the biotechnology industry in New England. NEBA serves as the regional policy and public affairs voice for the biotechnology and biopharmaceutical industry, and is committed to ensuring that New England remains a global leader in biotechnology and the life sciences.

NEBA members include the largest biotech associations in those states, including the Biotech Association of Maine, Connecticut United for Research Excellence (CURE), New Hampshire Bio/Medical Council, Rhode Island BioGroup, Massachusetts Biotechnology Council, Massachusetts High Technology Council, and the Biotech Association of Vermont (in formation).

To find out more about NEBA, visit

SOURCE New England Biotech Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
2. New Regional Biotech Association Formed
3. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
4. Strengthens Local Market Candidate Reach Through Acquisition
5. Strengthens Local Market Candidate Reach Through Acquisition
6. Strengthens Local Market Candidate Reach Through Acquisition
7. onTargetjobs Announces Acquisition of
8. A Magnetic Gift: Sumter Regional Hospital Receives New MRI as Charitable Donation From Siemens
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
11. Rigel to Present at Citis Biotech Day
Post Your Comments:
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
Breaking Biology Technology:
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
Breaking Biology News(10 mins):